Navigation

Rheumatoid arthritis - drugs for treatment after failure of a TNF inhibitor

Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor

Status: History
Expected date of issue: August 2010
Process: MTA
Topic area:
  • Musculoskeletal
 

NICE project team

Executive Lead: Andrew Dillon
Technical Lead: Whitney Miller
Communications manager: Tonya Gillis
Project manager: Jeremy Powell
Assessment Group / Evidence Review Group: West Midlands Health Technology Assessment Collaboration
Top


 

Provisional schedule

Consultation on draft scope by stakeholders: 8 April 2009
Closing date for invited submissions / evidence submission: 10 August 2009
1st appraisal committee meeting: 04 February 2010
2nd appraisal committee meeting: 06 April 2010
Top


 

Consultees and commentators

Consultees Commentators (no right to submit or appeal)

Manufacturers/sponsors

  • Abbott Laboratories (adalimumab)
  • Bristol-Myers Squibb (abatacept)
  • Roche Products (rituximab)
  • Schering-Plough (infliximab)
  • Wyeth Pharmaceuticals (etanercept)

Patient/carer groups

  • Arthritis & Musculoskeletal Alliance (ARMA)
  • Arthritis Care
  • National Rheumatoid Arthritis Society
  • South Asian Health Foundation

Professional groups

  • British Health Professionals in Rheumatology
  • British Society for Rheumatology
  • Primary Care Rheumatology Society
  • Royal College of Nursing
  • Royal College of Pathologists
  • Royal College of Physicians

Others

Department of Health

Welsh Assembly Government

General

  • Department of Health,√?¬†Social Services and Public Safety for Northern Ireland
  • NHS Quality Improvement Scotland

Possible comparator manufacturer(s)

  • Alliance Pharmaceuticals (penicillamine) (not participating - no CA&U form)
  • Almus Pharmaceuticals (sulfasalazine) (not participating - no CA&U form)
  • Arrow Generics (azathioprine) (not participating - no CA&U form)
  • Astellas (auranofin) (not participating - no CA&U form)
  • AstraZeneca UK (chloroquine)
  • Focus Pharmaceuticals (azathioprine) (not participating - no CA&U form)
  • Generics (UK) (azathioprine, sulfasalazine, penicillamine) (not participating - no CA&U form)
  • GlaxoSmithKline (azathioprine)
  • IVAX Pharmaceuticals (azathioprine, sulfasalazine) (not participating - no CA&U form)
  • Mayne Pharma (methotrexate) (not participating - no CA&U form)
  • Medac UK (methotrexate)
  • Novartis (ciclosporin)
  • Pfizer (methotrexate, sulfasalazine)
  • Roche Products (tocilizumab)
  • Sandoz (azathioprine) (not participating -no CA&U form)
  • Sanofi Aventis (hydroxychloroquine, leflunomide, sodium aurothiomalate)
  • Schering Plough (golimumab)
  • Teva UK (azathioprine, sulfasalazine, penicillamine) (declined to participate)
  • UCB Pharma (certolizumab pegol)
  • Waymade Healthcare (sulfasalazine) (not participating - no CA&U form)
  • Wockhardt UK (methotrexate) (not participating - no CA&U form)

Relevant research groups

  • Arthritis Research Campaign

Assessment Group

  • West Midlands Health Technology Assessment Collaboration

Associated Guideline Groups

  • Scottish Intercollegiate Guidelines√?¬† Network (SIGN)

Associated Public Health Groups

  • None

Top


 

Project history

Date Update

18 March 2009

√?¬†

The Technology Appraisal of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis after failure of a previous TNF-α inhibitor ended following the publication of the appeal panel decision in November 2008.√?¬† The Institute decided that a new appraisal of the above TNF-α inhibitors should be scheduled into the work programme and combined with a review of technology appraisal guidance 126 (rituximab) and 141 (abatacept).

√?¬†

Top


 

Key documents

This page was last updated: 25 August 2010

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.

Selected, reliable information for health and social care in one place

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.